white → yellow2 → orange1
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
25C-NBOH
2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-hydroxyphenyl)methyl]ethanamine
2C-C-NBOH, NBOH-2C-C
25C-NBOH is a synthetic psychedelic of the substituted phenethylamine class, produced through N-benzylation of the psychedelic 2C-C.citation needed First synthesized in 2011 by Martin Hansen at the University of Copenhagen, it has since appeared as a designer drug. It is known for producing predominantly visual and stimulating psychedelic effects, with serotonin receptor affinity comparable to its structural relative 25C-NBOMe.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~100 μg
Light100-500 μg
Moderate500-750 μg
Strong750-1000 μg
Heavy1000+ μg
25C-NBOH and related NBOH compounds are not orally bioavailable. A bitter, metallic taste and noticeable numbing of the mouth are commonly reported, with the numbness typically lasting around an hour after the dose is absorbed. This substance has a steep dose-response relationship, and subjective effects can vary considerably even between doses of similar size.
Duration
Onset15-45 minutes
Come Up30-90 minutes
After Effects3-6 days
Total5-7 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
25C-NBOH produces a stimulating psychedelic experience broadly typical of the NBOH series, combining euphoria, empathy, and a general alteration of perception with prominent visual effects visible with both open and closed eyes. The headspace tends toward insight and a softening of ego boundaries, though confusion can occur, and mental and physical stimulation often persists long enough to interfere with sleep.
Physical
The body experience is distinctly stimulating and can include restlessness, muscle tension, and alternating sweating and chills. Appetite is suppressed, pupils dilate, and insomnia is common while effects remain active.
Stimulation
Stimulation is both mental and physical, and can manifest as restlessness.
Uncomfortable
Cognitive
The mental state is euphoric and empathogenic, with an insight-oriented, introspective character and a softening of the sense of self. Confusion is reported by some users, particularly as perception becomes more altered.
Emotional
Visual
Visual effects are a core feature of the experience, spanning brightened colors and visuals that appear with eyes both open and closed.
Tactile
Tactile sensation is enhanced, with touch and texture feeling more pronounced.
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
In vitro receptor assays found that 25C-NBOH bound human 5-HT2A receptors with pKi 9.4 and activated them with pEC50 9.43. In the same study, its affinity at rat 5-HT2C receptors was lower (pKi 7.8). These measurements characterize receptor binding and functional activity in assay systems; they do not establish human pharmacokinetics, metabolism, clinical potency, or safety.1
Pharmacokinetics
There have been no studies on the pharmacokinetic profile of 25C-NBOH and the metabolism of 25C-NBOH is unknown.
Metabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-T-x compounds2C-x compounds5-MeO-xxT tryptaminesCaffeineCannabisDiphenhydramineDOx compoundsMAOIsMDMAMescalineMXE
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Develops almost immediately after ingestion.
Baseline Reset
Approximately 2 weeks in the absence of further consumption
Half Tolerance
Approximately 1 week
Cross Tolerance
Serotonergic psychedelics
Harm Potential
Addiction & Dependence
Psychological
Extremely Low25C-NBOH is generally not regarded as habit forming, and repeated use may make taking it again less appealing. Its use is usually self-limiting rather than reinforcing.
Physical
Extremely LowNo evidence of physical dependence or withdrawal symptoms has been documented.
Toxicity
Cardiovascular
Acute cardiovascular effects including elevated blood pressure, increased heart rate, abnormal heartbeat, and vasoconstriction occur during intoxication;citation needed these effects may pose significant risk at higher doses or in individuals with pre-existing cardiovascular conditions.
Thermoregulatory
Temperature regulation suppression and increased body temperature occur during intoxication, which may contribute to dangerous hyperthermia, particularly at high doses or in warm environments with physical activity.citation needed
Psychosis Risk
Anxiety and paranoia appear to occur more readily with 25C-NBOH than with many other psychedelics, possibly related to its stimulating properties. At high doses, confusion, amnesia, and sensory overload may occur, potentially increasing vulnerability to adverse psychological reactions.
Seizure Risk
Seizures are documented as a possible effect.citation needed The unpredictable dose-response relationship of this substance may contribute to seizure risk at unexpectedly high effect levels.
History & Culture
25C-NBOH was first synthesized and documented in 2011 by Martin Hansen at the University of Copenhagen. The compound is a derivative of the phenethylamine psychedelic 2C-C,citation needed distinguished by the addition of an N-benzyl group bearing a hydroxyl substituent on the benzyl…
Legality
By Country
Illegal1
United KingdomClass AControlled as a Class A substance under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all clause.14 Class A drugs carry the most severe penalties, including up to 7 years imprisonment for possession and life imprisonment for supply offenses.
Controlled / restricted3
BrazilControlled (Portaria SVS/MS nº 344)Added to Portaria SVS/MS nº 344 on December 10, 2018, which is Brazil's regulatory framework for controlled substances.3 Possession, distribution, and use are prohibited under federal law.
GermanyNpSG (Controlled)Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016.4 Production and importation with intent to market, administration to others, and commercial trading are criminally punishable.5 Possession is technically illegal but carries no criminal penalty.
SwitzerlandControlled (Verzeichnis E)Specifically named as a controlled substance under Verzeichnis E (Schedule E) of Swiss narcotics legislation.13 Unauthorized possession, production, and distribution are prohibited.
Not scheduled1
SwedenNot scheduledLäkemedelsverkets föreskrifter LVFS 2011:10 om förteckningar över narkotika, consolidated text current through HSLF-FS 2026:26; Förordning (1999:58) om förbud mot vissa hälsofarliga varor, consolidated by Sveriges riksdag through SFS 2026:1110; Narkotikastrafflag (1968:64), current through SFS 2024:797; Lag (1999:42) om förbud mot vissa hälsofarliga varor, current through SFS 2024:835.6789101112
The current LVFS 2011:10 schedule is amended through HSLF-FS 2026:26 and names 25B-NBOH, 25E-NBOH and 25I-NBOH but not exact 25C-NBOH; the current health-dangerous-goods ordinance is amended through SFS 2026:1110 and its complete Annex likewise does not name it. Under the current Swedish narcotics and health-dangerous-goods schedules, exact 25C-NBOH is unscheduled. The LVFS salts/isomers language extends listed substances and does not itself convert a related unlisted NBOH into a listed substance.
References
Source Pages
Citations
- Martin Hansen, Karina Phonekeo, James S Paine, Sebastian Leth-Petersen, Mikael Begtrup, Hans Bräuner-Osborne, & Jesper L Kristensen. (March 2014). Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chemical Neuroscience, 5(3), 243–9. https://doi.org/10.1021/cn400216u1
- Halberstadt AL, Chatha M, Klein AK, Wallach J, & Brandt SD. (2020). NBOMes-Highly Potent and Toxic Alternatives of LSD. https://doi.org/10.3389/fnins.2020.000781
- Agência Nacional de Vigilância Sanitária (ANVISA). (2018-12-10). Resolução da Diretoria Colegiada - RDC Nº 254, DE 10 DE DEZEMBRO DE 2018. Ministério da Saúde / ANVISA. https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2018/rdc0254_10_12_2018.pdf1
- Bundesministerium der Justiz und für Verbraucherschutz. (2016-11-26). Neue-psychoaktive-Stoffe-Gesetz (NpSG). Bundesministerium der Justiz und für Verbraucherschutz. https://www.gesetze-im-internet.de/npsg/BJNR261510016.html1
- § 4 NpSG. (2019). https://www.gesetze-im-internet.de/npsg/__4.html1
- NIH PubChem structured 25C-NBOH compound properties. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/25C-NBOH/property/IUPACName,MolecularFormula,CanonicalSMILES/JSON1
- NIH PubChem 25C-NBOH synonym record. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/25C-NBOH/synonyms/JSON1
- Läkemedelsverkets föreskrifter LVFS 2011:10, consolidated narcotics schedules. lakemedelsverket.se (n.d.). https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/lvfs/lvfs-2011-10-konsoliderad.pdf1
- Förordning (1992:1554) om kontroll av narkotika. riksdagen.se (n.d.). https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/forordning-19921554-om-kontroll-av-narkotika_sfs-1992-1554/1
- Förordning (1999:58) om förbud mot vissa hälsofarliga varor. riksdagen.se (n.d.). https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/forordning-199958-om-forbud-mot-vissa_sfs-1999-58/1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 25C-NBOH article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.